Medicenna Therapeutics (TSE:MDNA) Stock Price Passes Below Fifty Day Moving Average – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.39 and traded as low as C$0.38. Medicenna Therapeutics shares last traded at C$0.39, with a volume of 41,383 shares changing hands.

Medicenna Therapeutics Price Performance

The stock has a market capitalization of C$36.00 million, a PE ratio of -1.77 and a beta of 2.97. The stock’s 50 day moving average is C$0.39 and its two-hundred day moving average is C$0.60. The company has a debt-to-equity ratio of 4.79, a quick ratio of 4.65 and a current ratio of 1.52.

Medicenna Therapeutics (TSE:MDNA) last posted its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative return on equity of 219.30% and a negative net margin of 533,640.00%. On average, equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.